Financial Performance - Sinohealth Holdings Limited reported a significant increase in revenue, reaching approximately HKD 500 million, representing a year-on-year growth of 25%[2]. - The company achieved a net profit of HKD 80 million, which is a 15% increase compared to the previous year[2]. - Total revenue for FY 2022 reached RMB 356.668 million, representing a 10.4% increase from RMB 324.166 million in FY 2021[14]. - Profit for the year in FY 2022 was RMB 54.213 million, a decrease of 24.5% compared to RMB 71.978 million in FY 2021[14]. - The gross profit for FY 2022 was RMB 159.108 million, down from RMB 192.639 million in FY 2021[14]. - The Group's profit before tax decreased by approximately 43.0% from approximately RMB 95.5 million for the year ended 31 December 2021 to approximately RMB 54.5 million for the year ended 31 December 2022[130]. - The Group's profit for the year decreased by approximately 24.7% from approximately RMB 72.0 million for the year ended 31 December 2021 to approximately RMB 54.2 million for the year ended 31 December 2022[130]. - Adjusted net profit (non-HKFRS measure) for the year ended 31 December 2022 was approximately RMB 66.3 million, down from RMB 92.6 million in 2021, representing a decrease of approximately 28.5%[132]. - The adjusted net profit margin (non-HKFRS measure) decreased from 28.6% in 2021 to 18.6% in 2022[132]. - The Group's total cash and cash equivalents amounted to approximately RMB 409.3 million as of 31 December 2022, representing an increase of approximately 1,105.5% from 31 December 2021[134]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share within the next three years[2]. - Sinohealth is investing in new product development, with an allocation of HKD 50 million for R&D in telehealth technologies[2]. - The management provided guidance for the next fiscal year, projecting a revenue growth of 20% to 25%[2]. - The Group aims to enhance efficiency in the healthcare industry through advancements in big data, cloud computing, and artificial intelligence[16]. - The Group aims to establish a closed-loop system for data circulation between the standard and non-standard markets to enhance health management[55]. - The Group plans to expand the depth and breadth of data collection to connect more pharmaceutical and medical device retail markets, medical institutions, and physical examination centers[104]. - The Group aims to enhance cooperation with key customers and expand its product portfolio and business scale for sustainable development[89]. Research and Development - Research and development personnel accounted for 36% of the workforce, with 248 individuals dedicated to R&D[11]. - The company aims to strengthen independent innovation and invest in R&D for big data technology, AI, and cloud computing[32]. - The Group continues to invest in technology development to enhance product applicability, accuracy, and content portfolio based on customer feedback[23]. - The company aims to enhance its R&D investment in big data technology, artificial intelligence, and cloud computing to strengthen its technological innovation capabilities[33]. Operational Efficiency - Sinohealth has implemented new strategies to improve operational efficiency, aiming for a 10% reduction in operational costs[2]. - The Group has focused on enhancing its refined and standardized management to improve operational efficiency and market development efficiency[42]. - The Group's focus is on patient-oriented approaches, implementing a multi-level vertical cloud layout that integrates prevention, treatment, maintenance, and overall health management[61]. Data and Technology - The database storage capacity surpassed 30TB, marking a nearly 50% year-on-year increase compared to 2021[11]. - More than 4 billion pieces of data were collected in 2022, reflecting an approximate 48% increase year-on-year compared to 2021[11]. - The data cleansing rate by the middleware exceeded 97%, with a data accuracy rate of over 99%, achieving a leading position in the industry[20]. - The Group has built 38 master databases covering data related to industry regulation, medicine, pharmacy, and life sciences[20]. - The Group's AI-MDT system has been recognized for its systematic and comprehensive approach to physical examination reports, indicating strong market potential[78]. Corporate Governance and Management - The company has a strong management team with diverse backgrounds in healthcare, finance, and engineering[152][156]. - The board includes independent directors who provide oversight and independent judgment, enhancing corporate governance[158]. - The management team is committed to ensuring effective operations and strategic direction for the group[150]. - The Group has established various internal professional committees to promote employees' professional development and encourage information exchange[146]. Customer and Market Insights - The number of pharmacy stores covered by the data collection network exceeded 72,000, spanning 299 cities in 29 provinces, with 80% able to access data in real-time[11]. - The number of partnering pharmacies reached 1,225, a year-on-year increase of 14.3% compared to 2021[20]. - The number of pharmacy consumers managed through the SIC platform reached 273,533, representing a 35.5% year-on-year growth[92]. - The Group serves over 2,000 customers across major industrial enterprises, including pharmaceutical and medical device manufacturers and retailers[42]. Challenges and Risks - A significant portion of the Group's revenue is derived from medical product manufacturer clients, which poses a risk if demand for healthcare insight solutions declines[174]. - The Group's reliance on partnering pharmacies for retail data may compromise the quality of data analysis if inaccuracies occur[174]. - The Group's financial performance and future prospects may be adversely affected by potential design or performance defects in its technology infrastructure[174]. Future Outlook - The Group is confident in achieving stable growth in performance for 2023, leveraging its resilience and strong management team developed during the pandemic[46]. - The Group expects rapid growth in its medical data, physical examination data, and innovative pharmaceutical and medical device data, forming a closed-loop healthcare industry database[117]. - The Group plans to upgrade and enhance its SaaS products, targeting a completion by 31 December 2025, with an investment of approximately HK$172.5 million, representing 50.8% of the total planned expenditure[180].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 截至2022年12月31日止年度之 年度業績公告 | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 財務摘要 | | 本集團的收入由截至 2021 年 12 月 31 日止年度約人民幣 324.2 百萬元增加約 至截至 2022 年 12 月 31 日止年度約人民幣 356.7 百萬元。 | | 本集團截至 2022 年 12 月 31 日止年度的溢利約為人 ...

Company Overview - Sinohealth Holdings has become the largest healthcare insight solution provider in China, partnering with over 60,000 retail pharmacy stores and storing over 25TB of data in its "Tiangong No.1" platform[21]. - The company provides customized and standardized digital intelligence solutions to over 900 corporate clients, including more than 60 top medical product manufacturers[22]. - 2022 is a milestone year as the company was successfully listed on the Stock Exchange on July 12, 2022, marking a new phase of development[23][24]. Financial Performance - Total revenue increased by approximately 13.3% to approximately RMB121.21 million in the first half of 2022 compared to RMB106.98 million in the first half of 2021[28]. - Gross profit decreased by approximately 8.6% to RMB56.65 million in the first half of 2022, compared to RMB62.01 million in the first half of 2021[28]. - Net profit fell by approximately 57.2% to RMB5.29 million in the first half of 2022, down from RMB12.37 million in the same period of 2021[28]. - Adjusted net profit decreased by approximately 62.4% to RMB9.48 million in the first half of 2022, compared to RMB25.20 million in the first half of 2021[28]. - Other income and gains decreased by approximately 38.0% to approximately RMB10.86 million, primarily due to a decline in government grants from approximately RMB10.93 million in the first half of 2021 to approximately RMB3.79 million in the first half of 2022[80]. - The Group recorded revenue of approximately RMB121.21 million in the first half of 2022, representing an increase of approximately 13.3% compared to the same period last year[79]. - The company reported a profit before tax of 53,926,000 for the six months ended June 30, 2022[130]. - Profit for the period was RMB 5,287,000, a significant decrease of 57.3% compared to RMB 12,367,000 in 2021[131]. Revenue Breakdown - Data Insight Solutions segment revenue grew by approximately 64.3% to approximately RMB83.55 million in the first half of 2022, up from RMB50.86 million in the same period of 2021[28]. - SaaS segment revenue rose by approximately 45.8% to approximately RMB16.64 million in the first half of 2022, compared to RMB11.41 million in the first half of 2021[28]. - Revenue from Data-driven Publications and Events decreased by approximately 53.0% to approximately RMB21.02 million in the first half of 2022, down from RMB44.71 million in the same period of 2021[28]. - Revenue from Data Insight Solutions amounted to approximately RMB 83.55 million in the first half of 2022, representing an increase of approximately 64.3% compared to the same period in 2021, contributing approximately 68.9% to total revenue[50]. - Revenue from Data-driven Publications and Events was approximately RMB21.02 million in the first half of 2022, a decrease of approximately 53.0% compared to the same period in 2021, contributing about 17.3% to total revenue[56]. - Revenue from SaaS amounted to approximately RMB16.64 million in the first half of 2022, representing an increase of approximately 45.8% compared to the same period in 2021, with its contribution to total revenue rising to approximately 13.8%[59]. Client and Market Expansion - The number of corporate clients increased by 29 to 286 in the first half of 2022, driven by the expansion into DTP pharmacies and e-commerce markets[51]. - The Group plans to enhance its SaaS products in pharmacies and expand the installation base and user numbers in the second half of 2022[33]. - The introduction of new data insight solutions will target DTP pharmacies, e-commerce, and county market insights to attract more customers[37]. - The Group will host more industry events in the second half of 2022 to enhance interaction among ecosystem participants and stabilize revenue from its business segments[37]. Technological Development - The Group aims to invest in product and technological innovation, including the development of new products and services in Data Insight Solutions[34]. - The Group plans to enhance its SaaS products, including launching an upgraded SIC system and a new Smart Analysis Cloud product[38]. - The Smart Health Management Cloud product AI-MDT has been fully launched, aimed at expanding cooperation with public and private physical examination institutions[40]. - The Group will continue to invest in big data, cloud computing, and AI technologies to strengthen its technological capabilities and market share[39]. Operational Metrics - As of June 30, 2022, there were 213 backlog contracts with an expected revenue of approximately RMB 101.48 million to be recognized in the second half of 2022[52]. - As of June 30, 2022, more than 1,100 retail pharmacies and over 50,000 stores signed up for the Smart Retail Cloud's SIC service, reflecting increases of approximately 35% and 36% year-on-year, respectively[60]. - The number of partnering pharmacies increased to 1,257 as of June 30, 2022, covering 63,234 retail stores, which is a year-on-year increase of approximately 34.7%[64]. - Pharmacy staff using the SIC mobile app reached approximately 192,000, representing a year-on-year increase of approximately 28.0%[64]. - Pharmacy consumers managed by pharmacies through SIC reached approximately 231 million, a year-on-year increase of approximately 77.7%[64]. Research and Development - The Group invested heavily in R&D in the first half of 2022, focusing on the development and commercialization of its proprietary aPaaS products[68]. - Research and development costs rose to RMB 28,520,000, reflecting a 18.9% increase from RMB 24,084,000 in the previous year[184]. Cash Flow and Financial Position - Cash and cash equivalents increased by approximately 190.0% to approximately RMB98.47 million as of June 30, 2022, indicating a strong cash position[92]. - The Group's cash flow from operations was approximately RMB 1.84 million, a decrease of about 95.3% compared to the same period last year[101]. - The Group's gearing ratio as of June 30, 2022, was approximately 22.6%, down from 24.3% as of December 31, 2021[101]. - The Group did not have any bank borrowings or unutilized banking facilities as of June 30, 2022[101]. - The company reported a net increase in cash and cash equivalents of RMB 64,239,000, contrasting with a decrease of RMB (2,794,000) in the prior year[154]. Shareholder Information - The total number of shares issued as of the report date is 451,770,000[116]. - Mr. Wu Yushu and Ms. Wang Lifang collectively hold 268,987,500 shares, representing approximately 59.54% of the company's interest[116]. - Wellmark Link Limited holds 181,237,500 shares, accounting for 55.06% of the company's interest[120]. - The report indicates that no other directors or chief executives have disclosed interests or short positions in the company's shares[118]. Corporate Governance - The Company has adopted the Model Code for Directors' securities transactions and confirmed compliance since the Listing Date[111]. - The Company has maintained good corporate governance practices, ensuring transparency and accountability to shareholders[109]. - The Board believes that the current structure of having the same individual serve as both Chairman and CEO will not impair the balance of power and authority within the Group[109].